Abstract:
The present invention provides for the isolation and characterization of canine interleukin-5 (IL-5) and nucleic acid and amino acid sequences of IL-5. More particularly, recombinant DNA molecules encoding for canine interleukin-5 and conservative variants are provided. In other aspects, the invention provides cells comprising the recombinant vectors, and methods for producing canine IL-5 comprising the steps of inserting a transcription regulatory sequence proximal to the IL-5 gene in a cell comprising that gene, and stimulating production of IL-5 through the regulatory sequence.
Abstract:
The present invention provides methods and compositions for decreasing IgE levels in dogs. The methods and compositions are useful for treating allergic symptoms in dogs. The invention may comprise chimeric canine anti-IgE monoclonal antibody compositions and methods for using the compositions in the treatment of allergy. In preferred embodiments, the compositions of the present invention may act by binding soluble IgE in plasma, or by inhibiting IgE from binding to receptors on mast cells, B cells, and basophils.
Abstract:
The present invention provides methods and compositions for decreasing IgE levels in dogs. The methods and compositions are useful for treating allergic symptoms in dogs. The invention may comprise chimeric canine anti-IgE monoclonal antibody compositions and methods for using the compositions in the treatment of allergy. In preferred embodiments, the compositions of the present invention may act by binding soluble IgE in plasma, or by inhibiting IgE from binding to receptors on mast cells, B cells, and basophils.
Abstract:
The present invention provides methods and compositions for decreasing IgE levels in dogs. The methods and compositions are useful for treating allergic symptoms in dogs. The invention may comprise chimeric canine anti-IgE monoclonal antibody compositions and methods for using the compositions in the treatment of allergy. In preferred embodiments, the compositions of the present invention may act by binding soluble IgE in plasma, or by inhibiting IgE from binding to receptors on mast cells, B cells, and basophils.
Abstract:
The present invention provides canine heavy chain and light chain (both .lambda. and .kappa.) variable domain nucleic acids and polypeptides. The present invention also provides caninized antibodies comprised of the presen t disclosed canine variable domain framework sequences and CDRs specific for a n antigen obtained from antibodies from other than canines (preferably mouse). The invention also provides methods of making caninized antibodies and using them. This disclosure specifically describes caninized antibodies that are useful in the treatment of canine allergy. The general process of caninizati on permits the development of useful therapeutics, which includes but is not limited to allergy, osteoarcomma's and lymphomma's.
Abstract:
The present invention provides canine heavy chain and light chain (both .lambda. and .kappa.) variable domain nucleic acids and polypeptides. The present invention also provides caninized antibodies comprised of the presen t disclosed canine variable domain framework sequences and CDRs specific for a n antigen obtained from antibodies from other than canines (preferably mouse). The invention also provides methods of making caninized antibodies and using them. This disclosure specifically describes caninized antibodies that are useful in the treatment of canine allergy. The general process of caninizati on permits the development of useful therapeutics, which includes but is not limited to allergy, osteoarcomma's and lymphomma's.